Endocrine Imbalances and Steroid Therapies in Cachexia Reviewed

Cachexia is a severe, involuntary weight loss syndrome characterized by muscle wasting and fat depletion, often associated with chronic diseases like cancer, heart failure, and COPD. It significantly impairs quality of life and increases mortality. While its multifactorial nature is recognized, the specific role of endocrine abnormalities and the efficacy of steroid pharmacotherapy in managing this complex condition have not been comprehensively synthesized. This review addresses the critical need to understand how hormonal dysregulation contributes to cachexia and evaluate the potential of steroid-based treatments.

The review consistently highlighted that cachexia is frequently accompanied by significant endocrine dysregulation, particularly reduced levels of anabolic hormones like testosterone, insulin-like growth factor 1 (IGF-1), and dehydroepiandrosterone (DHEA), observed in a substantial proportion of patients. Conversely, elevated levels of catabolic hormones, such as cortisol, were also frequently noted. Anabolic-androgenic steroids (AAS), including testosterone and oxandrolone, demonstrated promising results in increasing lean body mass and improving muscle strength, with several studies reporting a 5-10% increase in lean mass and up to 15% improvement in grip strength over treatment periods ranging from 8 to 24 weeks. Glucocorticoids, while sometimes used for symptomatic relief, were found to potentially exacerbate muscle catabolism in the long term. The most significant finding was that targeted restoration of anabolic hormonal balance, especially with agents like testosterone, consistently showed potential for improving body composition and functional capacity, with a notable reduction in fatigue scores by 20-25% in treated groups compared to controls.